JUNSHI BIO (01877): First patient dosed in Phase III clinical trial of JS203 combined with chemotherapy for the treatment of diffuse large B-cell lymphoma
Junshi Biosciences (01877) announced that the first patient has been dosed in a randomized, open-label, multicenter Phase III clinical study of the company's product, a recombinant humanized anti-CD20 and CD3 bispecific antibody (code: JS203), in combination with chemotherapy versus rituximab in combination with chemotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). This study is the first registrational clinical study of JS203.
JUNSHI BIO (01877) announced that the first patient has been dosed in the company's randomized, open-label, multicenter Phase III clinical study of its product, a recombinant humanized anti-CD20 and CD3 bispecific antibody (code: JS203), in combination with chemotherapy versus rituximab in combination with chemotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). This study is the first registrational clinical study of JS203.
Related Articles
DYNAGREEN ENV (01330) net profit attributable to shareholders for the first three quarters was approximately RMB 732 million, up 16.9% year on year.
American Express Company (AXP.US) plans to cut 3,500 jobs, with cost reduction and efficiency gains coexisting with concerns over a consumption slowdown.
Dongjiang Environmental (00895) Announces Q3 Results: Net Loss Attributable to Shareholders of RMB 144 Million, Widened by 48.89% YoY
DYNAGREEN ENV (01330) net profit attributable to shareholders for the first three quarters was approximately RMB 732 million, up 16.9% year on year.
American Express Company (AXP.US) plans to cut 3,500 jobs, with cost reduction and efficiency gains coexisting with concerns over a consumption slowdown.
Dongjiang Environmental (00895) Announces Q3 Results: Net Loss Attributable to Shareholders of RMB 144 Million, Widened by 48.89% YoY
